Not independent
Tenure on this board
13.1 yrs
Also a director at
Jazz Pharmaceuticals PLC (JAZZ)
Meeting calendar
TBPH · Special meeting · Friday, September 18, 2026
Theravance Biopharma Inc
9 nominees · 3 ballot items.
Three proposals: (1) Special resolution to approve the Merger Agreement, Plan of Merger, related amendments to the company’s memorandum and articles and increase of authorized share capital and consummation of related transactions including CVR Agreement; (2) Ordinary advisory resolution to approve merger-related compensation to named executive officers (golden parachute); (3) Ordinary resolution to adjourn the Extraordinary General Meeting if necessary to solicit additional proxies, address supplemental proxy materials, lack quorum or as required by law.
Market cap
$880M
1Y TSR
+34.0%
Board grade
C
Record date
Jul 31, 2026
Filing
DEFM14A
Filed Aug 21, 2026 · DEFM14A
Proposals
On the ballot3
- 1
The Merger Proposal
ManagementBoard: FORSpecial resolution to approve and authorize the Agreement and Plan of Merger with Zymeworks, the Plan of Merger, the merger of the Company with Merger Sub so the Company will be the surviving company, amendments to the Memorandum and Articles of Association, an increase in authorized share capital, and the consummation of related transactions including the Contingent Value Rights Agreement (CVR Agreement).
- 2
The Advisory Merger-Related Compensation Proposal
ManagementBoard: FORNon-binding, advisory (ordinary) resolution to approve the merger-related compensation payable to the Company’s named executive officers as disclosed in the proxy statement (golden parachute disclosure).
- 3
The Adjournment Proposal
ManagementBoard: FOROrdinary resolution to approve adjournment of the Extraordinary General Meeting to a later date or dates if necessary to solicit additional proxies, provide required supplemental proxy materials, obtain quorum, or as required by law.
Director elections
Nominees on the ballot9
Not independent
Tenure on this board
New nominee
Not independent
Tenure on this board
New nominee
Not independent
Tenure on this board
New nominee
Not independent
Tenure on this board
New nominee
Independent
Tenure on this board
3.5 yrs
Also a director at
Maravai Lifesciences Holdings Inc (MRVI)4D Molecular Therapeutics Inc (FDMT)Anaptysbio Inc (ANAB)
Independent
Tenure on this board
12.2 yrs
Also a director at
Praxis Precision Medicines Inc (PRAX)
Independent
Tenure on this board
6.1 yrs
Also a director at
Karyopharm Therapeutics Inc (KPTI)Mereo Biopharma Group PLC (MREO)Freenome Inc (FRNM)
Independent
Tenure on this board
8.5 yrs
Also a director at
Arvinas Inc (ARVN)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Madison Avenue Partners, LP | 17.7% | 9,212,252 | $157M |
| 2 | Weiss Asset Management LP | 14.4% | 7,457,060 | $127M |
| 3 | Newtyn Management, LLC | 6.6% | 3,434,191 | $58M |
| 4 | Irenic Capital Management LPActivist | 5.3% | 2,760,948 | $47M |
| 5 | BlackRock, Inc. | 4.3% | 2,226,938 | $38M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,771,493 | $30M |
| 7 | BlackRock, Inc. | 2.8% | 1,448,053 | $25M |
| 8 | STATE STREET CORP | 2.6% | 1,328,584 | $23M |
| 9 | TWO SIGMA INVESTMENTS, LP | 2.4% | 1,225,587 | $21M |
| 10 | ACADIAN ASSET MANAGEMENT LLC | 2.3% | 1,174,910 | $20M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Theravance Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Artiva Biotherapeutics IncARTV
Annual meeting·Sep 8, 2026·$545M
Ocugen IncOCGN
Special meeting·Sep 21, 2026·$471M
Canopy Growth CorpCGC
Annual meeting·Sep 25, 2026·$444M
Replimune Group IncREPL
Annual meeting·Sep 15, 2026·$1.3B
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$372M
Anavex Life Sciences CorpAVXL
Annual meeting·Sep 24, 2026·$290M
Reference
Frequently asked questions
- When is the Theravance Biopharma Inc 2026 special meeting?
- Theravance Biopharma Inc (TBPH) holds its 2026 special shareholder meeting on Friday, September 18, 2026.
- What is the record date for the Theravance Biopharma Inc 2026 meeting?
- The record date for the Theravance Biopharma Inc 2026 meeting is Friday, July 31, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Theravance Biopharma Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Theravance Biopharma Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Theravance Biopharma Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Theravance Biopharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.